

# Non-Insulin Therapies for Diabetes-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/N4D93F425BDMEN.html>

Date: May 2018

Pages: 157

Price: US\$ 2,480.00 (Single User License)

ID: N4D93F425BDMEN

## Abstracts

### Report Summary

Non-Insulin Therapies for Diabetes-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Non-Insulin Therapies for Diabetes industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Non-Insulin Therapies for Diabetes 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Non-Insulin Therapies for Diabetes worldwide, with company and product introduction, position in the Non-Insulin Therapies for Diabetes market

Market status and development trend of Non-Insulin Therapies for Diabetes by types and applications

Cost and profit status of Non-Insulin Therapies for Diabetes, and marketing status

Market growth drivers and challenges

The report segments the global Non-Insulin Therapies for Diabetes market as:

Global Non-Insulin Therapies for Diabetes Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Non-Insulin Therapies for Diabetes Market: Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-glucosidase Inhibitors

Amylin Agonists

Biguanides

Dipeptidyl Peptidase-4 (DPP4) Inhibitors

Glinides / Meglitinides

GLP-1 Analogs / GLP-1 Agonists

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

Sulfonylureas

Thiazolidinediones

Others

Global Non-Insulin Therapies for Diabetes Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacy

Retail Pharmacies

Online Pharmacy

Others

Global Non-Insulin Therapies for Diabetes Market: Manufacturers Segment Analysis  
(Company and Product introduction, Non-Insulin Therapies for Diabetes Sales Volume, Revenue, Price and Gross Margin):

GSK

Eli Lilly

Sumitomo Dainippon Pharma

Intarcia Therapeutics

Servier

Jiangsu Hansoh Pharmaceutical

Novo Nordisk  
Emisphere  
Uni-Bio Science Group  
Takeda  
3SBio  
Merck  
Dong-A Pharmaceutical  
Luye Pharma Group  
Eurofarma  
Geropharm  
Alkem Labs  
SatRx  
Pfizer  
Jiangsu Hengrui Medicine

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF NON-INSULIN THERAPIES FOR DIABETES**

- 1.1 Definition of Non-Insulin Therapies for Diabetes in This Report
- 1.2 Commercial Types of Non-Insulin Therapies for Diabetes
  - 1.2.1 Alpha-glucosidase Inhibitors
  - 1.2.2 Amylin Agonists
  - 1.2.3 Biguanides
  - 1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  - 1.2.5 Glinides / Meglitinides
  - 1.2.6 GLP-1 Analogs / GLP-1 Agonists
  - 1.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  - 1.2.8 Sulfonylureas
  - 1.2.9 Thiazolidinediones
  - 1.2.10 Others
- 1.3 Downstream Application of Non-Insulin Therapies for Diabetes
  - 1.3.1 Hospital Pharmacy
  - 1.3.2 Retail Pharmacies
  - 1.3.3 Online Pharmacy
  - 1.3.4 Others
- 1.4 Development History of Non-Insulin Therapies for Diabetes
- 1.5 Market Status and Trend of Non-Insulin Therapies for Diabetes 2013-2023
  - 1.5.1 Global Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023
  - 1.5.2 Regional Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Non-Insulin Therapies for Diabetes 2013-2017
- 2.2 Sales Market of Non-Insulin Therapies for Diabetes by Regions
  - 2.2.1 Sales Volume of Non-Insulin Therapies for Diabetes by Regions
  - 2.2.2 Sales Value of Non-Insulin Therapies for Diabetes by Regions
- 2.3 Production Market of Non-Insulin Therapies for Diabetes by Regions
- 2.4 Global Market Forecast of Non-Insulin Therapies for Diabetes 2018-2023
  - 2.4.1 Global Market Forecast of Non-Insulin Therapies for Diabetes 2018-2023
  - 2.4.2 Market Forecast of Non-Insulin Therapies for Diabetes by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Non-Insulin Therapies for Diabetes by Types
- 3.2 Sales Value of Non-Insulin Therapies for Diabetes by Types
- 3.3 Market Forecast of Non-Insulin Therapies for Diabetes by Types

## **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Non-Insulin Therapies for Diabetes by Downstream Industry
- 4.2 Global Market Forecast of Non-Insulin Therapies for Diabetes by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Non-Insulin Therapies for Diabetes Market Status by Countries
  - 5.1.1 North America Non-Insulin Therapies for Diabetes Sales by Countries (2013-2017)
  - 5.1.2 North America Non-Insulin Therapies for Diabetes Revenue by Countries (2013-2017)
  - 5.1.3 United States Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 5.1.4 Canada Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 5.1.5 Mexico Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 5.2 North America Non-Insulin Therapies for Diabetes Market Status by Manufacturers
- 5.3 North America Non-Insulin Therapies for Diabetes Market Status by Type (2013-2017)
  - 5.3.1 North America Non-Insulin Therapies for Diabetes Sales by Type (2013-2017)
  - 5.3.2 North America Non-Insulin Therapies for Diabetes Revenue by Type (2013-2017)
- 5.4 North America Non-Insulin Therapies for Diabetes Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Non-Insulin Therapies for Diabetes Market Status by Countries
  - 6.1.1 Europe Non-Insulin Therapies for Diabetes Sales by Countries (2013-2017)
  - 6.1.2 Europe Non-Insulin Therapies for Diabetes Revenue by Countries (2013-2017)
  - 6.1.3 Germany Non-Insulin Therapies for Diabetes Market Status (2013-2017)

- 6.1.4 UK Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.1.5 France Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.1.6 Italy Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.1.7 Russia Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.1.8 Spain Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.1.9 Benelux Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 6.2 Europe Non-Insulin Therapies for Diabetes Market Status by Manufacturers
- 6.3 Europe Non-Insulin Therapies for Diabetes Market Status by Type (2013-2017)
  - 6.3.1 Europe Non-Insulin Therapies for Diabetes Sales by Type (2013-2017)
  - 6.3.2 Europe Non-Insulin Therapies for Diabetes Revenue by Type (2013-2017)
- 6.4 Europe Non-Insulin Therapies for Diabetes Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Non-Insulin Therapies for Diabetes Market Status by Countries
  - 7.1.1 Asia Pacific Non-Insulin Therapies for Diabetes Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Non-Insulin Therapies for Diabetes Revenue by Countries (2013-2017)
  - 7.1.3 China Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 7.1.4 Japan Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 7.1.5 India Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 7.1.6 Southeast Asia Non-Insulin Therapies for Diabetes Market Status (2013-2017)
  - 7.1.7 Australia Non-Insulin Therapies for Diabetes Market Status (2013-2017)
- 7.2 Asia Pacific Non-Insulin Therapies for Diabetes Market Status by Manufacturers
- 7.3 Asia Pacific Non-Insulin Therapies for Diabetes Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Non-Insulin Therapies for Diabetes Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Non-Insulin Therapies for Diabetes Revenue by Type (2013-2017)
- 7.4 Asia Pacific Non-Insulin Therapies for Diabetes Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 8.1 Latin America Non-Insulin Therapies for Diabetes Market Status by Countries
  - 8.1.1 Latin America Non-Insulin Therapies for Diabetes Sales by Countries (2013-2017)
  - 8.1.2 Latin America Non-Insulin Therapies for Diabetes Revenue by Countries

(2013-2017)

8.1.3 Brazil Non-Insulin Therapies for Diabetes Market Status (2013-2017)

8.1.4 Argentina Non-Insulin Therapies for Diabetes Market Status (2013-2017)

8.1.5 Colombia Non-Insulin Therapies for Diabetes Market Status (2013-2017)

8.2 Latin America Non-Insulin Therapies for Diabetes Market Status by Manufacturers

8.3 Latin America Non-Insulin Therapies for Diabetes Market Status by Type

(2013-2017)

8.3.1 Latin America Non-Insulin Therapies for Diabetes Sales by Type (2013-2017)

8.3.2 Latin America Non-Insulin Therapies for Diabetes Revenue by Type (2013-2017)

8.4 Latin America Non-Insulin Therapies for Diabetes Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

9.1 Middle East and Africa Non-Insulin Therapies for Diabetes Market Status by Countries

9.1.1 Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Non-Insulin Therapies for Diabetes Revenue by Countries (2013-2017)

9.1.3 Middle East Non-Insulin Therapies for Diabetes Market Status (2013-2017)

9.1.4 Africa Non-Insulin Therapies for Diabetes Market Status (2013-2017)

9.2 Middle East and Africa Non-Insulin Therapies for Diabetes Market Status by Manufacturers

9.3 Middle East and Africa Non-Insulin Therapies for Diabetes Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Non-Insulin Therapies for Diabetes Sales by Type (2013-2017)

9.3.2 Middle East and Africa Non-Insulin Therapies for Diabetes Revenue by Type (2013-2017)

9.4 Middle East and Africa Non-Insulin Therapies for Diabetes Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

10.1 Global Economy Situation and Trend Overview

10.2 Non-Insulin Therapies for Diabetes Downstream Industry Situation and Trend



## Overview

### **CHAPTER 11 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

- 11.1 Production Volume of Non-Insulin Therapies for Diabetes by Major Manufacturers
- 11.2 Production Value of Non-Insulin Therapies for Diabetes by Major Manufacturers
- 11.3 Basic Information of Non-Insulin Therapies for Diabetes by Major Manufacturers
  - 11.3.1 Headquarters Location and Established Time of Non-Insulin Therapies for Diabetes Major Manufacturer
  - 11.3.2 Employees and Revenue Level of Non-Insulin Therapies for Diabetes Major Manufacturer
- 11.4 Market Competition News and Trend
  - 11.4.1 Merger, Consolidation or Acquisition News
  - 11.4.2 Investment or Disinvestment News
  - 11.4.3 New Product Development and Launch

### **CHAPTER 12 NON-INSULIN THERAPIES FOR DIABETES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 12.1 GSK
  - 12.1.1 Company profile
  - 12.1.2 Representative Non-Insulin Therapies for Diabetes Product
  - 12.1.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of GSK
- 12.2 Eli Lilly
  - 12.2.1 Company profile
  - 12.2.2 Representative Non-Insulin Therapies for Diabetes Product
  - 12.2.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.3 Sumitomo Dainippon Pharma
  - 12.3.1 Company profile
  - 12.3.2 Representative Non-Insulin Therapies for Diabetes Product
  - 12.3.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Sumitomo Dainippon Pharma
- 12.4 Intarcia Therapeutics
  - 12.4.1 Company profile
  - 12.4.2 Representative Non-Insulin Therapies for Diabetes Product
  - 12.4.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of



## Intarcia Therapeutics

### 12.5 Servier

#### 12.5.1 Company profile

#### 12.5.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.5.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

### Servier

### 12.6 Jiangsu Hansoh Pharmaceutical

#### 12.6.1 Company profile

#### 12.6.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.6.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

### Jiangsu Hansoh Pharmaceutical

### 12.7 Novo Nordisk

#### 12.7.1 Company profile

#### 12.7.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.7.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

### Novo Nordisk

### 12.8 Emisphere

#### 12.8.1 Company profile

#### 12.8.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.8.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

### Emisphere

### 12.9 Uni-Bio Science Group

#### 12.9.1 Company profile

#### 12.9.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.9.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of

### Uni-Bio Science Group

### 12.10 Takeda

#### 12.10.1 Company profile

#### 12.10.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.10.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin

### of Takeda

### 12.11 3SBio

#### 12.11.1 Company profile

#### 12.11.2 Representative Non-Insulin Therapies for Diabetes Product

#### 12.11.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin

### of 3SBio

### 12.12 Merck

#### 12.12.1 Company profile

#### 12.12.2 Representative Non-Insulin Therapies for Diabetes Product

12.12.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Merck

12.13 Dong-A Pharmaceutical

12.13.1 Company profile

12.13.2 Representative Non-Insulin Therapies for Diabetes Product

12.13.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Dong-A Pharmaceutical

12.14 Luye Pharma Group

12.14.1 Company profile

12.14.2 Representative Non-Insulin Therapies for Diabetes Product

12.14.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Luye Pharma Group

12.15 Eurofarma

12.15.1 Company profile

12.15.2 Representative Non-Insulin Therapies for Diabetes Product

12.15.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eurofarma

12.16 Geropharm

12.17 Alkem Labs

12.18 SatRx

12.19 Pfizer

12.20 Jiangsu Hengrui Medicine

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

13.1 Industry Chain of Non-Insulin Therapies for Diabetes

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

14.1 Cost Structure Analysis of Non-Insulin Therapies for Diabetes

14.2 Raw Materials Cost Analysis of Non-Insulin Therapies for Diabetes

14.3 Labor Cost Analysis of Non-Insulin Therapies for Diabetes

14.4 Manufacturing Expenses Analysis of Non-Insulin Therapies for Diabetes

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

### 16.1 Methodology/Research Approach

#### 16.1.1 Research Programs/Design

#### 16.1.2 Market Size Estimation

#### 16.1.3 Market Breakdown and Data Triangulation

### 16.2 Data Source

#### 16.2.1 Secondary Sources

#### 16.2.2 Primary Sources

### 16.3 Reference

## I would like to order

Product name: Non-Insulin Therapies for Diabetes-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/N4D93F425BDMEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N4D93F425BDMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970